依美溴铵 | 3614-30-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 依美溴铵
• 英文名称: emepronium bromide
• 英文别名: Emepronium；Restenacht；4,4-diphenylbutan-2-yl-ethyl-dimethylazanium;bromide
• CAS: 3614-30-0
• 化学式: Br*C₂₀H₂₈N
• 分子量: 362.353
• InChiKey: UVKFSMBPRQBNCH-UHFFFAOYSA-M

物化性质

• 熔点：
  204°
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (S)-recipavrin 、 溴乙烷 生成 依美溴铵
  参考文献：
  名称：

  AASEN, ARNE JZHUSTORGEN;SSNJELDERUR, LISE, ACTA CHEM. SCAND., 42,(1988) N 3, 206-210

  摘要：

  DOI：

文献信息

• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• NOVEL BRONCHODILATING DIAZAHETEROARYLS
  申请人：Johansson Martin

  公开号：US20120040942A1

  公开（公告）日：2012-02-16

  The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.

  这项发明涉及具有通式（I）的新化合物，这些化合物可用于治疗由支气管痉挛引起的疾病或疾病，例如慢性阻塞性肺疾病（COPD）和哮喘。
• [EN] NOVEL BRONCHODILATING DIAZAHETEROARYLS<br/>[FR] NOUVEAUX DIAZAHÉTÉROARYLES BRONCHODILATATEURS
  申请人：RESPIRATORIUS AB

  公开号：WO2010097410A1

  公开（公告）日：2010-09-02

  The invention relates to novel compounds having the general formula (I), and which compounds are useful to treat a disorder or disease characterized by bronchoconstriction, e.g. COPD and asthma.

  这项发明涉及具有通式（I）的新化合物，这些化合物可用于治疗由支气管痉挛引起的疾病或疾病，例如慢性阻塞性肺疾病（COPD）和哮喘。
• Quaternary ammonium compounds
  申请人：——

  公开号：US20030158176A1

  公开（公告）日：2003-08-21

  Novel quaternary ammonium compounds of the formula 1 and any stereoisomers thereof, wherein R 1 , R 2 and R 3 independently represent C 1 -C 6 alkyl, optionally substituted with phenyl or hydroxyl, or both, and wherein any two of R 1 , R 2 and R 3 may form a ring together with the quaternary ammonium nitrogen; R 4 represents —H, —CH 3 , or —CO—R 4-1 ,wherein R 4-1 represents —(C 1 -C 4 alkyl), —(C 1 -C 4 alkoxy), or —NR 4-2 R 4-3 , wherein R 4-2 and R 4-3 independently represent —H or —(C 1 -C 4 alkyl); R 5 , R 6 and R 7 independently represent —H, —OCH 3 , —OH, —CONH 2 , —SO 2 NH 2 , —F, —Cl, —Br, —I, —CF 3 , or —(C 1 -C 4 alkyl), optionally substituted with one or two —OH, —(C 1 -C 4 alkoxy), —COOH, or —CO—O—(C 1 -C 3 alkyl); and X − represents an anion of a pharmaceutically acceptable acid, the compounds for use as medicaments, use of the compounds for the manufacture of specific medicaments, and pharmaceutical compositions comprising the compounds. The present invention also concerns a method of treatment involving administration of the compounds.

  新颖的四元铵化合物的化学式为1，及其所有立体异构体，其中R1、R2和R3分别表示C1-C6烷基，可选择地取代为苯基或羟基，或两者兼有，且其中任意两个R1、R2和R3可与四元铵氮形成环；R4表示—H，—CH3，或—CO—R4-1，其中R4-1表示—(C1-C4烷基)，—(C1-C4烷氧基)，或—NR4-2R4-3，其中R4-2和R4-3独立地表示—H或—(C1-C4烷基)；R5、R6和R7独立地表示—H，—O ，—OH，—CONH2，—SO2NH2，—F，—Cl，—Br，—I，—CF3，或—(C1-C4烷基)，可选择地取代为一个或两个—OH，—(C1-C4烷氧基)，—COOH，或—CO—O—(C1-C3烷基)；X-表示药学上可接受的酸的阴离子，这些化合物用作药物，用这些化合物制造特定药物的用途，以及包含这些化合物的药物组合物。本发明还涉及涉及给药的治疗方法。
• CAYALYST SYSTEM AND MANUFACTURING METHOD OF CYCLIC CARBONATE BY THE SAME
  申请人：Industrial Technology Research Institute

  公开号：US20150119584A1

  公开（公告）日：2015-04-30

  A catalyst system and a method for manufacturing cyclic carbonate by the same are provided. The catalyst system includes a transition metal salt containing a halo group, an acetate group, or a combination thereof, and an organic phosphine ligand. The molar ratio of the organic phosphine ligand to the transition metal salt is greater than 0 and less than or equal to 50.

  提供了一种催化剂系统和通过该系统制备环状碳酸酯的方法。该催化剂系统包括含有卤素基团、乙酸基团或二者的过渡金属盐和有机膦配体。有机膦配体与过渡金属盐的摩尔比大于0且小于或等于50。